Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6689623 | 0.91 | ADRB2 (0.31) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL5153 | 0.86 | — | — | |
| SCHEMBL3308133 | 0.83 | ADRB2 (0.31) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL4344426 | 0.82 | — | — | |
| SCHEMBL27401809 | 0.78 | — | — | |
| SCHEMBL3304257 | 0.77 | ADRB2 (0.30) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL3308458 | 0.74 | ADRB2 (0.33) | ADRB2HTR1ASLC6A2HTR2ASLC6A4 | |
| SCHEMBL16193885 | 0.74 | — | — | |
| SCHEMBL4753 | 0.74 | — | — | |
| SCHEMBL5264819 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843566-A | Polysubstituted benzene derivative, composition and use thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | claimed |
| EP-1647555-B1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | INST RADIATION MED AMMS PLA (CN) | 2011-04-20 | — | — | EP | claimed |
| US-7727965-B2 | C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same | HAINAN YANGPU NEW & SPECIAL MEDICINE CO., LTD. (CN) | 2010-06-01 | — | — | US | claimed |
| US-20080293642-A1 | C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same | INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2008-11-27 | — | — | US | claimed |
| EP-1647555-A1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-04-19 | — | — | EP | claimed |
| CN-117843566-A | Polysubstituted benzene derivative, composition and use thereof | 康迈迪森(北京)医药科技有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-108948019-B | Focal adhesion kinase inhibitors and uses thereof | 广东东阳光药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| EP-2755975-A1 | NEW ENZYME INHIBITOR COMPOUNDS | Proximagen Limited (GB) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013038189-A1 | NEW ENZYME INHIBITOR COMPOUNDS | PROXIMAGEN LTD. (GB) | 2013-03-21 | — | — | WO | disclosed |
| EP-1647555-B1 | THE C-GLYCOSYLISOFLAVONES HAVING ALKYLAMINOALKOXYL SUBSTITUENT, THE PREPARATION AND THE USE OF THE SAME | INST RADIATION MED AMMS PLA (CN) | 2011-04-20 | — | — | EP | disclosed |
| US-7727965-B2 | C-glycosylisoflavones having alkylaminoalkoxyl substituent, preparation and use of the same | HAINAN YANGPU NEW & SPECIAL MEDICINE CO., LTD. (CN) | 2010-06-01 | — | — | US | disclosed |
| WO-2002018404-A2 | NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| WO-2001012587-A1 | AMINOSALICYLCLIC ACID AMIDES AND THEIR USE FOR COMBATING ORGANISMS THAT ARE HARMFUL TO PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-02-22 | — | — | WO | disclosed |
| EP-0177287-B1 | PYRIMIDINE DERIVATIVES, PROCESSES FOR PREPARATION THEREOF AND COMPOSITION OF THE SAME | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-12-05 | — | — | EP | disclosed |
| US-4727073-A | CEREBOVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-23 | — | — | US | disclosed |
| US-4698340-A | TREATMENT OF CEREBROVASCULAR DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-10-06 | — | — | US | disclosed |
| EP-0177287-A2 | Pyrimidine derivatives, processes for preparation thereof and composition of the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-04-09 | — | — | EP | disclosed |
| EP-0169712-A2 | New pyrimidine derivatives, processes for preparation thereof and composition containing the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293642-A1 | C-Glycosylisoflavones Having Alkylaminoalkoxyl Substituent, Preparation and Use of the Same | UGCG, PIGO, GPI | ADRB2 1154/4885HTR1A 3438/4885SLC6A2 1524/4885 |
| US-20140275063-A1 | NEW ENZYME INHIBITOR COMPOUNDS | XDH, MAOB, MAOA | ADRB2 741/4885HTR1A 576/4885SLC6A2 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.